Dr. Srinivasan on Targeted Therapies for Non-Clear Cell RCC

Ramaprasad Srinivasan, MD, PhD
Published: Tuesday, Feb 23, 2016



Ramaprasad Srinivasan, MD, PhD, staff clinician, Urologic Oncology Branch, National Cancer Institute, discusses the need for targeted therapies for patients with non-clear cell renal cell carcinoma (RCC) and the types of agents these patients are likely to benefit from.

Over the last several years, researchers have examined if VEGF inhibitors, which demonstrate significant activity in patients with clear cell RCC, would be as effective in patients with non-clear cell RCC. These agents do have a benefit in a small subset of patients with non-clear cell RCC, Srinivasan explains. The biology of non-clear cell RCC, which is made up of multiple subtypes, needs to be better studied to understand which targets will benefit from therapy.

Promising findings are being reported with inhibitors that target MET, a pathway found in patients with the type 1 papillary RCC subtype, he adds.

<<< View more from the 2016 GU Cancer Symposium



Ramaprasad Srinivasan, MD, PhD, staff clinician, Urologic Oncology Branch, National Cancer Institute, discusses the need for targeted therapies for patients with non-clear cell renal cell carcinoma (RCC) and the types of agents these patients are likely to benefit from.

Over the last several years, researchers have examined if VEGF inhibitors, which demonstrate significant activity in patients with clear cell RCC, would be as effective in patients with non-clear cell RCC. These agents do have a benefit in a small subset of patients with non-clear cell RCC, Srinivasan explains. The biology of non-clear cell RCC, which is made up of multiple subtypes, needs to be better studied to understand which targets will benefit from therapy.

Promising findings are being reported with inhibitors that target MET, a pathway found in patients with the type 1 papillary RCC subtype, he adds.

<<< View more from the 2016 GU Cancer Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x